AU2013209364A1 - Companion animal compositions including lipoic acid and methods of use thereof - Google Patents

Abstract

The invention encompasses compositions and methods for treating or preventing disorders in companion animals, where the compositions and methods include feeding the companion animal a composition including lipoic acid or a salt thereof.

Description

COMPANION ANIMAL COMPOSITIONS INCLUDING LIPOIC ACID AND METHODS OF USE THEREOF This is a divisional of AU 2009335096, the entire contents of which are incorporated 5 herein by reference. CROSS REFERENCE TO RELATED APPLICATIONS [001] This application is a continuation-in-part of pending application Ser. No. 11/154,210, filed June 16, 2005, which is a continuation of application Ser. No. 09/978,132 filed October 16, 2001, which issued as U.S. patent number 6,914,071, 10 which is a continuation-in-part of application Ser. No. 09/922,660 filed August 6, 2001, which claims benefit of Provisional Application Ser. No. 60/253,448 filed November 28, 2000 and Provisional Application Ser. No. 60/244,504, filed October 31, 2000, each of which is incorporated herein by reference in its entirety. 15 FIELD OF THE INVENTION [002] The invention encompasses compositions and methods for treating or preventing disorders in companion animals, wherein the compositions and methods include feeding the companion animal a composition including lipoic acid or a salt thereof. 20 BACKGROUND OF THE INVENTION [003] Companion animals such as dogs and cats seem to suffer from aging problems. Some of these are manifested in commonplace sayings. One of these is "you can't teach an old dog new tricks." This saying arises from the observation that as dogs age, their 25 mental capacity seems to diminish as well as physical abilities. Mental activities associated with thinking, learning and memory seem to be lessened (Cummings B J, Head E, Ruehl W, Milgram N W, Cotman C W 1996: The canine as an animal model of aging and dementia; Neurobiology of aging 17:259-268). Additionally, behavioural change can be manifested in the aging animals in association with the changing mental 30 capacity. Many causes have been assigned to this lessening of capacity. 1 [004] These losses in capacity are generally observed in aged canines and felines. Dogs of seven years or older and felines of seven years or older are considered aged and can experience this problem. 1A WO 2010/078324 PCT/US2009/069686 [005] An inmportant indicator of animal health is the body composition of the animal. An unhealthy diet and/or an unhealthy lifestyle can result in the animal having an unhealthy proportion of body fat, particularly in relation to lean muscle in the body. It is thought that a body fat amount in excess of 30% by weight indicates that the animal is unhealthy. particularly if the amount of body fat is in excess of 35% by weight. 10061 The invention encompasses pet food compositions for companion animals, which have increased therapeutic and prophylactic efficacy over currently marketed companion food products. SUMMARY OF THE INVENTION [0071 The inventors have developed food compositions and methods of using the compositions for treating or preventing disorders in animals. 10081 In accordance with the invention, there is a companion pet diet meeting ordinary nutritional requirements of an adult pet and further comprising a sufficient amount of an antioxidant or mixture thereof to inhibit the onset of deterioration of the mental capacity of said companion pet in its aged years. 1009] Another embodiment encompasses a food composition for a companion animal, which includes lipoic acid or a salt thereof. [00101 Another embodiment of the invention is a method for inhibiting the deterioration of the mental capacity of an aged companion pet, which comprises feeding said pet in his adult years an antioxidant or mixture thereof at sufficient levels to accomplish this inhibition. 100111 In further accordance with the invention is a companion pet diet meeting ordinary nutritional requirements of an adult companion pet and further comprising an antioxidant selected from the group consisting of Vitamin E, Vitam in C, alpha-lipoic acid, 1-carnitine and any mixtures thereof in quantities sufficient to inhibit the deterioration of the mental capacity of said pet in its aged years [00121 A still f-rther embodiment of the invention is a method for increasing the mental WO 2010/078324 PCT/US2009/069686 [00131 Another embodiment of the invention is a method for increasing the mental capacity of an adult companion pet, which comprises feeding the pet an amount of an antioxidant or mixture thereof sufficient to increase the mental capacity of said pet. 100141 In all of these methods, it is desirable to administer the antioxidant or mixture thereof in the diet of the animal. DETAILED DESCRIPTION OF THE INVENTION General Description 100151 The invention encompasses food compositions including an amount of, lipoic acid or a salt thereof 100161 In certain embodiments, the effective amount is at least about 25 ppm. [00171 In certain embodiments, the effective amount is at least about 50 ppm. 100181 In certain embodiments, the effective amount is at least about 100 ppm. [00191 In certain embodiments, the effective amount is about 100 ppm to about 600 ppm. [00201 In certain embodiments, the effective amount is about 100 ppm to about 200 ppm. [0021] In certain embodiments, the companion animal is a dog. [00221 In certain embodiments, the companion animal is a cat. 100231 In certain embodiments, the effective amount is effective to prevent or treat a degenerative joint condition in a companion animal. [00241 In crain embodiments, the degenerative joint condition is osteoarthritis. [00251 n certain embodiments, the degenerative joint condition is cartilage damage. 100261 in certain embodiments. the effective e amount is effective to prevent or treat kidney rLatddsresi opno nml WO 2010/078324 PCT/US2009/069686 [00271 In ertain embodiments. the effetiv e amount is effective to enhnmee palatability to a companion animal. 100281 In certain embodiments, the effective amount is effective to maintain or promote a healthy body composition in a companion animal. 100291 In certain embodiments, the effective amount is effective for inducing weight loss in a companion animal. [00301 In certain embodiments, the effective amount is effective for inducing loss of body fat in a companion animal. [00311 In certain embodiments, the effective amount is effective for increasing the percentage of lean muscle mass in a companion animal. [00321 In certain embodiments, the composition further comprises a protein, fat, carbohydrate, fiber, and combinations thereof [00331 In certain embodiments, the composition is a dog food. [00341 In certain embodiments., the composition is a cat food. 100351 In certain embodiments, the composition is a food, a nutritional diet, a supplement, an animal treat, or a toy. [00361 In certain embodiments, the composition is in the form of'a moist food. [00371 In certain embodiments, the composition is in the form of a dry food. 100381 The term "companion animal" used in the present invention includes any non-human animal suitable for being kept as a pet by humans including a dog, a cat, and a rodent. The compositions of the invention are in certain embodiments for the treatment of cats and/or dogs. [00391 The tcrm "dog" includes those dogs,. which are companion animals such as Canis familiari., working dogs and the like. The term dog is synonymous w ith the term canine. [0040] The term "cat" includes those cats, which are, comparison animals known as dornestic cats or house eats. [0041] The term "rodent" includes, but is not limited to, hamsters, mice, rats, guinea pigs, e'is, rabbits, hedge hogs, ferrets, chinchillas etc. -4 - WO 2010/078324 PCT/US2009/069686 Compositions of the Invention 100431 One embodiment of the invention encompasses compositions for companion animals includingan effec amount of lipoic acid to prevent or treat a degenerative joint condition in a companion animal. 100441 As used herein, the terms "lipoic acid or a salt thereof' includes, but is not limited to, for example. alpha-lipoic acid, a racemic mixture of lipoic acids, a lipoate salt, ester. amide or derivative thereof, for example as described in U.S. patent number 5,621,117. In various embodiments, the lipoic acid can be administered in a composition comprising a wet or dry food composition, which may be in the form of a moist food, dry food, supplement or treat. 100451 The lipoic acid may be incorporated therein or on the surface of any food composition, such as, by spraying or precipitation thereon or may be added to the diet by way of snack, supplement, treat or in the liquid portion of the diet such as water or another fluid. The lipoic acid may be administered as a powder, solid or as a liquid including a gel. An important aspect is that the animal be provided an effective amount of the lipoic acid to provide a positive effect. Typically, the source of lipoic acid is present in the composition in an amount of up to an amount which remains non-toxic to the animal. [00461 The quantity of alpha-lipoic acid can vary from at least about 25 ppm, about 50 ppm, about 100 ppm, about 200 ppm, about 300 ppm, about 500 ppm. about 700 ppm, about 900 ppm, about 1100 ppm, about 1200 ppm, about 1400 ppm, about 1600 ppm, about 1800 ppm, about 2000 ppm, about 2200 ppm, about 2400 ppm, about 2600 ppm, about 2800 ppm, about 3000 ppm, or about 3500 ppm. In various embodiments, the range of lipoic acid that can be administered dogs is about 150 ppm to about 4500 ppm. In various embodiments, the range of lipoic acid that can be administered cats is about 65 ppm to about 2600 ppm. In certain illustrative emubodiments, quantities can vary from about 100 ppm to an amount which remains non-toxic to the pet. Inotner embodiments, a range is from about 100 ppm to about 200 pp>m. helh anma on the diet WO 2010/078324 PCT/US2009/069686 100481 -he compositions of the imention include lipoic acid or salt thereof in an amount e :eeti\e to treat or prev ent a degenerate e joimt condition. [00491 The lipoic acid or salt thereof is present at a concentration that is not deleterious to the intended animal's health. Thus, for example, the lipoic acid or salt thereof is present at a concentration that does not cause undesirable or toxic effects. [00501 The invention is based upon the novel disco cry that adding lipoic acid or salt thereof to a composition for consumption by a companion animal enhances palatability of the composition and increases the likelihood that an animal will consume the composition. Adding lipoic acid or salt thereof to a composition for consumption also increases the ingestion frequency and ingestion rate of the composition. [0051] The composition can be a liquid or a solid food. When the composition is a liquid, the lipoic acid or salt thereof can be admixed with other components. Where the composition is solid, the lipoic acid may be coated on the composition, incorporated into the composition, or both. [00521 In various embodiments, the lipoic acid or salt thereof may be added to the animal's food. In various embodiments, the lipoic acid or salt thereof may be added to the animal's food by a compounder or manufacturer at a site or by an animal s caregiver prior to feeding the animal. In various embodiments, the lipoic acid or salt thereof may be added during the processing of an animal's food, such as during and/or after mixing of other components of the composition that is then packaged and made available to consumers. Such processing may include extrusion, canning. baking, and the like or any other method or process of producing pet foods that is known in the art. In various embodiments, the lipoic acid or salt thereof may be contributed by a natural source likc ai animal or plant component, or the lipoic acid or salt thereof may be contributed by a synthetically derived source, or the lipoic acid or salt thereof may be c ntributed by a mixture of natural and synthetic sources. [00531 The compositions in addition to lipoic acid or a salt thereof include at east one comp onent suitable for consumption by a companion animal including, but not limited to, fats, elements. and mixtures thereof One of ordinary skill in the art can select the amnoun1 and ty pe of WO 2010/078324 PCT/US2009/069686 food ingredients for a typic Ifood based upon the dietary requirements of the animal. for example, the animal's species, age, size, weight. health, and function. 100541 The food ingredient part of the food composition can include up to about 100% of any particular food ingredient or can include a mixture of food ingredients in various proportions. In certain embodiments, the food composition includes a combination of food ingredients in amounts of about 0 wt. % to about 50 wt. %,o fat, about 0 wt. % to about 75 wt. % carbohydrate., about 0 wt. % to about 95 wt. % protein, about 0 wt. % to about 40 wvvt. % dietary fiber, and about 0 wt. % to about 15 wt. % of one or more nutritional balancing agents. [00551 In certain embodiments, the fat and carbohydrate food ingredient is obtained from a variety of sources such as animal fat, fish oil, vegetable oil, meat, meat by-products, grains, other animal or plant sources, and mixtures thereof. Grains include wheat, corn, barley, and rice. [00561 In certain embodiments, the protein food ingredient is obtained from a variety sources such as plants, animals, or both. Animal protein includes meat, meat by-products, dairy, and eggs. Meats include the flesh from poultry, fish, and animals such as cattle., swine, sheep, goats, and the like, meat by-products include lungs, kidneys, brain, livers, stomachs, and intestines. The protein food ingredient may also be free amino acids and/or peptides. Preferably, the protein food ingredient includes meat, a meat by-product, dairy products, or eggs. [0057] In certain embodiments, the fiber food ingredient is obtained from a variety of sources such as vegetable fiber sources, for example, cellulose, beet pulp, peanut hulls, and soy fiber. 100581 In certain embodiments, the nutritional balancing agents are obtained from a variety of sources known to skilled artisans, for example, vitamin and mineral supplements and food ingredients. Vitamins and minerals can be included in amounts required to avoid deficiency and maintain health. These amounts are readily available in the art. The National Research Council (NRC) pro ides recommended amounts of such nutrients for farm animals. See. e.g., Nutrient Re quirements of Swine (10th Rev. Ed., Na t'l Academy Press Wash. D.C'. 1998) Nutrient Requiremn ts of Poultry (9th Rev. Ed Nat'l Acdemy Press, Wash. D.C 1994). Nutrient Requiemens ~. Hor 5th ev, d., N , cdem rss, ash.D.C.. I9 h Aeia Feed ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~~~~~~~~J Jo4O'K (A(')p11&rcomne mut o uhntint u lg n ca..S~ m~im ed onrl ffcalIn..Ofiil ubiaton p.1-7-7(00) WO 2010/078324 PCT/US2009/069686 B6, vitamin B12, vitaNmin ), biotin, vitamin K, folic acid, inositol, niacin, and pantothenic acid. Minerals and trace elements useful as food additives include calcium, phosphorus, sodium, potassium, magnesium, copper, zinc, chloride, iron. selenium. iodine, and iron. 100591 In certain embodiments, the food compositions may contain additional ingredients such as vitamins, minerals, fillers., palatability enhancers, binding agents, flavors, stabilizers, emulsifiers, sweeteners. colorants, buffers, salts, coatings, and the like known to skilled artisans. Stabilizers include substances that tend to increase the shelf life of the composition such as preservatives, synergists and sequestrants, packaging gases, stabilizers, emulsifiers, thickeners, gelling agents, and humectants. Examples of emulsifiers and/or thickening agents include gelatin, cellulose ethers, starch, starch esters, starch ethers, and modified starches. Specific amounts for each composition component, food ingredient, and other ingredients will depend on a variety of factors such as the particular components and ingredients included in the composition; the species of animal; the animal's age., body weight., general health, sex, and diet; the animal's consumption rate; the type of disease or condition being treated; and the like. Therefore, the component and ingredient amounts may vary widely and may deviate from the preferred proportions described herein. [00601 In one illustrative embodiment, the composition may, for example, in addition to lipoic acid or a salt thereof also include at least one of the following: (a) about 0% to about 75% carbohydrate, (b) about 2% to about 50% fat, (c) about 0% to about 40% dietary fiber, and (d) about 0% to about 15% of one or more nutritional balancing agents. 100611 The diet fed to the adult companion pet, for example, canine and feline is the standard normal diet fed to an animal of that ge. Below is a typical diet for a canine of 1 to 6 years of age. Table 1: Illustrativ e Companion Animal Pet Food Composition jCid-,It - 8 ... i ... of dr matter) WO 2010/078324 PCT/US2009/069686 Fat (0 of dry matter) 15 Phosphorous (% of dry matter) 0.6 Sodium (% of dry matter) 0.3 [00621 The compositions can contain additional ingredients intended to maintain or improve the health of the animal, for example, supplements, medications, herbs, holistic drugs and compositions, and the like. [00631 The composition of the invention may include one or more additional ingredients to prevent or treat one or more diseases or conditions. [00641 The component in the diet, which accomplishes this, is an antioxidant or mixture thereof. An antioxidant is a material that quenches a free radical. Examples of such materials include foods such as Ginkgo Biloba, citrus pulp, grape pomace, tomato pomace, carrot and spinach, all preferably dried as well as various other materials such as beta-carotene, selenium, coenzyme Q1O (ubiquinone), lutein, tocotrienols, soy isoflavones, S-adenosylmethionine, glutathione, taurine, N-acetylcysteine, Vitamin E, Vitamin C, alpha-lipoic acid, 1-carnitine and the like. Vitamin E can be administered as a tocopherol or a mixture of tocopherols and various derivatives thereof such as esters like vitamin E acetate, succinate, palmitate, and the like. The alpha form is preferable but beta, gamma and delta forms can be included. The d form is preferable but racemic mixtures are acceptable. The forms and derivatives will function in a Vitamin E like activity after ingestion by the pet. Vitamin C can be administered in this diet as ascorbic acid and its various derivatives thereof such as calcium phosphate salts, cholesteryl salt, 2-m-nonophosphate, and the like which will function in a vitamin C like activity after ingesting by the pet. They can be in any form such as liquid, semisolid, solid and heat stable form. Alpha lipoic acid can be administered into the diet as alpha lipoic acid or asa lipoate derivative as in U.S. Pat. No. 5,621,117, raceic mxtures, salts, esters or aides thereof. nitine n b administered in the diet and various deriv ative~s of. earnitine such as the salts such as the hydrochloride, fumarate and succinates, as well as acetylated carni tine, and the like can be used. [0065] The quantities administered in the diet al as wt % (dryi matter basis) of the diet, are WO 2010/078324 PCT/US2009/069686 ppm of Vita min can be sed. A preferred range of about 500 to about 1,000 ppm can be employed. Although not necessary, a maximum of about 2000 ppm or abou It 1500 ppm is generally not exceeded. With respect to Vitamin C at least about 50 ppm is used, desirably at least about 75 ppm and more desirable at least about 100 ppm. A non-toxic maximum can be employed. The quantity of alpha-lipoic acid can vary from at least about 25, desirably at least about 50 ppm, more desirably about 100 ppm. Maximum quantities can vary from about 100 ppm to an amount which remains non-toxic to the pet. A preferred range is from about 100 ppm to about 200 ppm. For 1-camitine about 50 ppm, desirably about 200 ppm, more desirably about 300 ppm for canines are a useful minimum. For felines, slightly higher minimums of 1-carnitine can be employed such as about 100 ppm, 200 ppm, and 500 ppm. A non-toxic maximum quantity can be employed, for example, less than about 5,000 ppm. For canines, lower quantities can be employed, for example, less than about 5,000 ppm. For canines, a preferred range is about 200 ppm to about 400 ppm. For felines, a preferred range is about 400 ppm to about 600 ppm. Beta-carotene at about 1-15 ppm can be employed. Selenium at about 0.1 up to about 5 ppm can be employed. Lutein at least about 5 ppm can be employed. Tocotrienols at least about 25 ppm can be employed. Coenzyme Q10 at least about 25 ppm can be employed. S adenosylmethionine at least about 50 ppm can be employed. Taurine at least about 1000 ppm can be employed. Soy isoflavones at least about 25 ppm can be used. N-acetylcysteine at least about 50 ppm can be used. Glutathione at least about 50 ppm can be used. Gingko Biloba at least 50 ppm of extract can be used. [00661 The following are raw ingredients that are high in ORAC (Oxygen radical absorbing capacity) content: Spinach pomace, Tomato pomace. Citrus Pulp, Grape Pomace, Carrot granules, Broccoli, Green tea, Ginkgo Biloba and Corn gluten meal. 100671 When added to the diet as 1% inclusions (for a total of 5% subsittiion for a low ORAC ingredient such as corn) theyv increased the OPAC content of the overall diet and increased the OPAC content of the plasma of the animals which ate the diet containing these components. Preferably, any ingredient with an OPAC content >25 pamole of Trolox equivalents per gram of dry matter could be used if added at 1% combination with four other 1% ingredients for a total of 5% addition to the diet. In certain embodiments, the compositions further include an effective WO 2010/078324 PCT/US2009/069686 chondroitin sulfate, Iethylsulfonylnethane ("MSM"), creatine. antioxidants, Perna cana1 licula, omega-3 fatty acids, omega-6 fatty acids and mixtures thereof. 100681 In various embodiments, a supplement including an effective amount of lipoic acid or a salt thereof further includes an effective amount of at least one substance including aspirin, anti inflammatories such as ibuprofen, COX-2 inhibitors, and other medicinal and pharmaceutical compositions and combinations thereof. Supplements include, but are not limited to, a feed used with another feed to improve the nutritive balance or performance of the total. Supplements include compositions that are fed undiluted as a supplement to other feeds, offered free choice with other parts of an animal's ration that are separately available, or diluted and mixed with an animal's regular feed to produce a complete feed. The AAFCO, for example, provides a discussion relating to supplements in the American Feed Control Officials, Inc. Official Publication, p. 220 (2003). Supplements may be in various forms including, for example, powders, liquids, syrups, pills, and encapsulated compositions. 10069] In certain embodiments, the composition can be a treat. Treats include compositions that are given to an animal to entice the animal to eat during a non-meal time, for example, dog bones for canines. Treats may be nutritional wherein the composition includes one or more nutrients and may have a food-like composition. Non-nutritional treats encompass any other treats that are non-toxic. The composition or components are coated onto the treat, incorporated into the treat, or both. Treats of the invention can be prepared by an extrusion or baking process similar to those used for dry food. Other processes also may be used to either coat the composition on the exterior of existing treat forms or inject the composition into an existing treat form. In certain embodiments, the composition can be a toy. Toys include chewable toys such as artificial bones. The lipoic acid or a salt thereof can form a coating on the surface of the toy or on the surface of' a opponent of the toy, be incorporated partia ly or fully throughout the toy, or both. In one embodiment, the lipoic acid or a salt thereof is orally accessible by the intended user. There are a wide range of suitable toys currently marketed, for example, U.S. Pat. No. 5,339271 ,U.S. Pat. No. 5,419,283. and references disclosed therein. This inventon provides -V i - WO 2010/078324 PCT/US2009/069686 consumable toys, for example, rawhides and various artificial bones. The invention preferably provides toys for use by a dog or a cat. Preparation of the Compositions of the invention 100701 The compositions of the invention may be prepared in a canned or wet form using conventional food preparation processes known to skilled artisans. Typically, ground animal proteinaceous tissues are mixed with the other ingredients such as fish oils, cereal grains, balancing ingredients, special purpose additives (e.g.. vitamin and mineral mixtures, inorganic salts, cellulose and beet pulp, bulking agents, and the like) and water in amounts sufficient for processing. These ingredients are mixed in a vessel suitable for heating while blending the components. Heating of the mixture is effected using any suitable manner, for example, direct steam injection or using a vessel fitted with a heat exchanger. Following the addition of the last ingredient, the mixture is heated to a temperature of about 50 'F to about 212 'F. Temperatures outside this range are acceptable but may be commercially impractical without use of other processing aids. When heated to the appropriate temperature, the material will typically be in the form of a thick liquid. The thick liquid is filled into cans. A lid is applied, and the container is hermetically sealed. The sealed can is then placed into conventional equipment designed to sterilize the contents. Sterilization is usually accomplished by heating to temperatures of greater than about 230 'F for an appropriate time depending on the temperature used, the composition, and similar factors. The compositions of the present invention can be added to the food compositions before, during, or after preparation. [00711 Food compositions may be prepared in a dry form using conventional processes known to skilled artisans. Typically, dry ingredients such as animal protein, plant protein, grains, and the like are ground and mixed together. Moist or liquid ingredients, including fats, oils, animal protein, water, nd the like are then added to and mixed with the dry mix, The mixture is hen processed into kibbles or similar dry pieces. Kibhie is often formed using an extrusion process in which the mixture of dry and wet ingredients is subjected to mechanical work at a high pressure and temiperature and forced through small openings anid cut off into kibble by~ a rotating knife.

WO 2010/078324 PCT/US2009/069686 baking process, rather than extrusion, w herein the dough is placed into a mold before dry-heat processing. The food compositions can be in the form of a treat using an extrusion or baking process similar to those described above for dry food or a toy such a: those disclosed in U.S. Patent Nos. 5,339,771 and 5,419,283. The compositions of the present invention can be added to the food compositions before, during, or after preparation. Methods of Treating or Preventing Disorders with Compositions of the Invention 100721 The invention also encompasses methods of treating or preventing certain disorders by administering a therapeutically or prophylactically effective amount of a composition including lipoic acid or a salt thereof to a companion animal in need thereof. [00731 Adding significant quantities of an antioxidant or mixture thereof to the companion adult pet diet can bring about delay of the onset of demonstrative changes in the behaviour, particularly the deterioration of mental capacity, as specifically shown by problem-solving capacity, in an aged pet. The term, adult, is intended to mean, in general, a canine of at least I to 6 years and a feline of at least I to 6 years. An aged dog or cat is 7 years and above. 100741 The loss of mental capacity for canines and felines has been observed for a number of years. This loss of mental capacity is manifested in numerous ways. For a canine, for example, it can be manifested as disorientation, house soiling, altered sleep-wake patterns, decreased or altered interaction with humans and other pets, and inability to learn and concentrate. These conditions can be manifested in felines as well. Alzheimer's, as exhibited in man., is not found in canines and felines. [0075] Many theories have been advanced for this loss in mental capacity. To date, the inventors are unaware of any dietary course of action, which inhibits this loss of mental capacity or can actually bring about a positive change in mental capacity as measured by an objective parameter in dogs and eats. [0076} The invetor's hav succeeded in accomplishing delaying the onset of this deterioration. By sin the diet oft thr invention in adult companion pets it can be shown that aged pets WO 2010/078324 PCT/US2009/069686 respect to Cognitive Dysfunction Syndrome. its progress can be slowed in aged do's and clinical signs associated with this Syndrome can be controlled. Prophylaxes where appropriate and pets in need o 'these components are the target group. 100771 The invention is not limited to the particular methodology, protocols, and reagents described herein because they may vary. Further, the terminology used herein is for the purpose of describing particular embodiments only and is not intended to limit the scope of the present invention. As used herein and in the appended claims, the singular forms "a," "an," and "the" include plural reference unless the context clearly dictates otherwise. Similarly, the words "include", "includes", and "including" are to be interpreted inclusively rather than exclusively. Unless defined otherwise, all technical and scientific terms and any acronyms used herein have the same meanings as commonly understood by one of ordinary skill in the art in the field of the invention. Although any compositions, methods, articles of manufacture, or other means or materials similar or equivalent to those described herein can be used in the practice of the present invention, the preferred compositions, methods, articles of manufacture, or other means or materials are described herein. [00781 All patents, patent applications, publications, and other references cited or referred to herein are incorporated herein by reference to the extent allowed by law. The discussion of those references is intended merely to summarize the assertions made therein. No admission is made that any such patents, patent applications, publications or references, or any portion thereof, is relevant prior art for the present invention and the right to challenge the accuracy and pertinence of such patents, patent applications, publications, and other references is specifically reserved. EXAMPLES [0079] This invention can be further illustrated by the following examples of preferred embodiments thereof, although it wvill be understood that thes exaples are include merely for purposes of illustration and arc not intended to limit the scope of the invention unless otherwise specifically indicated. EXAMPLE 1 -14- WO 2010/078324 PCT/US2009/069686 Vitamin E and <32 ppm Vitamin C. The test diet had 900 ppm Vitamin E and 121 ppm V itami C, 260 ppm 1-carnitilne and 135 ppm alpha lipoic acid. Approximately I month after starting the diet, the first problem-solving task given to dogs was a liandmrk discrimination learning task, which is a test of spatial attention (Milgram et aL, 1999 Milgram, N. W., Adams, B., Callahan, H., Head, E., Mackay, B., Thirlwell, C., & Cotman (1999), C. W. Landmark Discrimination Learning in the Dog. Learning & Memory. 6:54-61). 100811 Landmark discrimination learning requires subjects to select a particular object based on proximity to an object. The initial learning, however, is based on the dogs' ability to learn an object discrimination task. We have previously found that the effects of age on discrimination learning depend on task difficulty. [0082] The adult dogs on the enriched diet made fewer errors than the adult dogs on the control food when learning the landmark 0 test (control mean=3 1.1, enriched mean= 15.1). The adult dogs proceeded on to landmark 1 and 2 testing, where the landmark is moved further away from the positive well. Adult dogs on enriched diet learned landmark 0-2 with less errors than those on the control (number of mean errors landmark 0+1+2 control=1 32.9: number of mean errors of dogs on enriched diet landmark 0+1+2=87.1). EXAMPLE 2 100831 Thirty (30) adult, random source, dogs were utilized for this study. Dogs were at least 10 months of age. not pregnant. not lactating and of reasonable body weight prior to start of test. Animals w crc randomized into 5 groups for dietary treatment with 3 males and 3 females per each group. [0084] All dogs were fed a control food (0 ppm dl-alpha-lipoic acid added) that met or exceeded all recommendations for nutrients as proposed by the American Association of Feed Control Officials (AAFCO 2000) during a 2 week prefeeding period (Table 2). Following the prefeeding period dogs were randomized into 5 treatment groups with one of the following dI-alpha lipoic acid target-inclusions (dry matter basis): 0 ppm, 150 ppm, 1500 ppm, 3000 ppm, 4500 ppm. Inl all diets, control and alpha lipoic acid, Vitamin E was added and was present at a level of 600- WO 2010/078324 PCT/US2009/069686 [0085] Test foods were the sole source of nutrients except for water. Fresh water was prove ided ad libitum. After dogs were selected and initial body weights taken, a food dose was calculated for each dog based on the expected ME of the food. Initial food dose calculations were based on the maintenance energy requirement (MER) for the dog modified by a factor to account for normal activity as calculated by the following formula: MER(kcal/day)= 1.6 x RER(Resting Energy Requirement) where: RER (kcal/day)=70 x body weight (kg)0.75 [00861 Dogs were weighed weekly and had food doses adjusted as needed in order to feed enough food to maintain their optimal body weight. Optimal body weight was determined to be 3 on a 5 point scale. If a dog did not maintain body weight within -10% of initial body weight, after adjustment of food dose, it was removed from the study. All measures of body weight and food intake were recorded. [00871 Samples were ground and 0.100 +/-0.001 g of sample was extracted twice into 5.0 mL phosphate buffer (10 mM Na 2

HPO

4 , 2 mM ethylenediaminetetraacetatic acid (EDTA), 0.9% NaCl, pH 7.4). 250 l, of extract was placed into a 5 mL glass centrifuge tube with a Teflon lined cap. 15 pL EDTA solution (100 mM EDTA, adjusted to p' 1 7.8 with about 1 M NaOl) and 50 .tL freshly prepared 5 mM dithioerythritol (DTE) were added. The solutions were vortexed and incubated at room temperature for 5 minutes. Then 10 tL of I M H 3

PO

4 and 2.0 mL diethyl ether were added. The tubes were capped, vortexed, and centrifuged at 1500 x g for 3 minutes at room temperature. The ether layer was transferred to a separate 5 mL glass centrifuge tube, while the aqueous layer was extracted twice more with 1.5 mL ether. All extractions from the same sample were combined. The extracts are then dried in a nitrogen evaporator in a water bath at room temperature. At this point, the samples wre ca pped and frozen overnight. 100881 The dried extracts were then thawed and reconstituted with 70 L SDS/ DTA solution (0.11% sodium dodecyl sulfate (SDS), 15 mM EDTA 0 .9% Na C) and 4 Lr frshly prepa red 1 mM DTE.750 pL of freshly prepared NaBH4 was then added to each tube. The tubes were vortexed and incubated at room temperature for 10 minutes.dAfter 10 minutes, the samples were frozen at -70 "C. Before the solutions were thawed, 20 L 2M HCl was added. After the solutions were thawed, 800 L1 100 mM NiH-CO3 was added. The solutions are vortexed and 5 WO 2010/078324 PCT/US2009/069686 pL of 100 mM monobromodiamane in acetonitrile solution (mBBr) was added. The solutions we~re then incubated in the dark for 90 minutes at room temperature. [00891 Excess mBBr and the DI F derivative were removed from the samples after incubation by extraction with 1.5 mL dichloromethane. The aqueous layer was placed on the HPLC. The lipoic acid was separated using a mobile phase that consisted of 30% acetonitrile, 1% acetic acid, adjusted to pH 3.95 with about 2M NHI40 1 1 and was pumped at a flow rate of 1.0 mL/min with an isocratic elution for 15 minutes per injection. This preparation assumes that the density of the extruded food is equal to I g/mL. [00901 Blood was collected aseptically for complete blood count. and blood biochemistry analysis 2 weeks prior to start and again at 0, 28. 56, 84, 112, 140 and 168 days of the study. In addition, 15 ml of whole blood was collected for isolation of lymphocytes at day 0, 28 and 84 of the dietary intervention. [00911 Heparinzed whole blood was layered onto a 50 ml Accuspin conical centrifuge tube (Sigma Chemical) and an equal volume of Phosphate buffered saline (PBS) was added. Samples were centrifuged at 700 g for 30 minutes without brake. The monocyte layer was harvested, transferred to a 15 ml conical centrifuge tube, resuspended in 1-3 ml of PB, and centrifuged as before (First wash). A second wash was performed as the first wash. Finally, cells were harvested and suspended in perchloric acid (10% w/v) and frozen at -70 "C until analysis. [00921 Samples were transferred from -70 "C freezer into a cooler with dry ice in it. Vials were centrifuged at 12,000 rpm for 5 minutes in a refrigerated centrifuge. An aliquot of supernatant for glutathione (GSH) analysis was transferred to a conical test tube. [00931 Derivatization of the acid soluble extracts was by the method of Reed and coworkers (Fariss et al) as modified by Jones (Jones et al) 100941 Briefly 150 .L extract or external standards were added into a 1.5 ml Eppendorf tub followd by addition of 20 T.;Gu-Glu internal standard and 50 paL IAA added followed byn mixing. The solution was adjusted to pH about 1 0 (purple color) by using KOHl-KHCO 3 working solution. Solutions were incubated 1 hr. under room temperature in the dark. Sanger's reagent was added at the same volume as of the total volume and the solution was incubated overnight p2 hrse in the dark at room temperature. -17.- WO 2010/078324 PCT/US2009/069686 100951 After incubation. the solution w as centrifuged at 1-2000 rpm for 5 minutes with the supernatant transferred into another 1 .5 ml eppendorf tube. 200 p L supernatant was added into an amber autovial, which had a 300 pL inlet, fixth top with a crimper for HI-PLC analysis. 100961 Solvents and separation conditions were as described (Fariss, Jones). Levels of GSH and CSSG were quantified relative to authentic standards. Gamma-glutamyl-glutamate was used as an internal standard to assess derivatization efficiency. [00971 Comparison of values for clinical chemistry, hematology and body weights vs baseline were analyzed by way of paired t-test on SAS for windows with significance set at P<0.05. Means of values at each measured time point were separated by a one-way ANOVA with significance set at P<0.05. The difference in GSH:GSSG between day 84 and baseline were analyzed between groups by way of SAS for windows in a one-way ANOVA with significance set at P<0.05. Results 100981 Concentrations of lipoic acid (ppm) in food as determined over 7 successive assays (0, 28, 56, 84, 112, 140, 168 days) were within the range of expected assay sensitivity and production parameters typically encountered at our facility (Table 2). [00991 The food intake data were unremarkable. Most animals in all groups ingested more food at 6 months, on average, than at the beginning of the study. Body weight data were unremarkable except that some weight loss occurred initially in the 4500 ppm inclusion group but that change appeared to reverse by 6 months time. Body condition scores did not appear to be affected by this minor loss of weight. 1901001 The routine physical examinations did not reveal any evidence of nutrition related abnormalities or dl-alpha-lipoic acid toxicity. All animals in the study population remained normal during the entire course of the study. Occasional vomiting was observed in several anirnals during the course of the study: however, a trend was not observed tha t would lead one to the conclusion that the vomiting may be attributable to lipoic acid. One animal, int the highest inclusion group, was dropped from the study at day 21 for weight loss and leukocytosis. The leukocytosis in thi animal had not resoled by the end of the stuy and is suped to be attributable to some other disease process. - 1 - WO 2010/078324 PCT/US2009/069686 100I101] When serum biochemistry values for days 28 56, 84. 112. 140, and 168 were compared with the initial values for the same group of dogs, several statistical differences were noted, however none of these were considered biologically significant because these values were within or very near the laboratory reference range and consistent trends over months were noted. Comparisons between the controls and the other treatment groups at each time period also revealed several statistical differences, however, none of these were considered biologically significant because these values were within or very near the clinical laboratory reference ranges and no trends were present. [001021 When the hematology values for days 28, 56. 84, 112, 140 and 168 were compared with the initial values for the same group of dogs, several statistical differences were noted; however, none of these were considered biologically significant because these values were within or very near the laboratory reference range and not trends were present. Comparison between the controls and the other treatment groups at each time period revealed several statistical differences; however, none of these were considered biologically significant because these values were within or very near the clinical laboratory reference ranges and no trends were present. GSH:GSSG ratio 1001031 The change in GSH:GSSG ratio over 84 days of feeding displayed a significant overall effect of diet (P=0.024) with all supplemented groups having an increase in the ratio (Table 3). ANOVA revealed a significant difference, compared to the basal food. for the lowest and highest inclusions, however, the largest numerical increase was in the lowest inclusion level. That is to say, the changes in the GSHI:GSSG ratios for the highest and lowest inclusion were significantly different from the change observed over this same time period in the basal food. Ratios for 4 points could not be determined at day 84 as no GSSG was detectable in an of these sanple1s (1 control, 3 treatment groups). As such the values fr supplementedl groups may have displayed even higher ratios of GISH:GSSG if the assay had bee sensitive enough to detect the low levels of GSSG at day 84. TABLE 2 n' sio Rae Aera. Sandrd c ation; Targ t 19- WO 2010/078324 PCT/US2009/069686 (ppm) 0 ppm 24 ppm 7 NA 150 ppm 151 ppm 13 101 1,500 ppm1 1471 ppm 113 98 3,000 ppm 2869 ppm 250 96 4,500 ppm 4176 ppm 642 93 TABLE 3 Change In Mean Ratio Of GSH:GSSG From Day 0 To Day 84 In Dogs Consuming DL-Alpha Lipoic Acid In An Extruded Food Inclusion Difference in N P value GSH:GSSG ratio day 0 to day 84 Inclusion compared to baseline food 0 pprn -9.2 -!- 26 5* N \ 1506ppm 70 -- 20 6 0003 1- 0-ppm 4-- 6 310 ppm 4-(- 0 4 45500 ppm 50-- 4* 00 .... ..-. ..

WO 2010/078324 PCT/US2009/069686 I dog in the control and 4,500 ppm group had no detectable GSSG at day 84 while 2 dogls in tie 3,000 ppm group had no detectable GSSG at day 84. [00104] Further observations with respect to alpha-lipoic acid are applicable. Chronic feeding of alpha-lipoic acid in diet is safe and effective. It improves the reduced glutathione (GSH) to oxidized glutathione (GSSG) ratio. The chronic administration of alpha-lipoic acid in the diet can be for periods of one, two, three, four, five, or six months minimum up through a period of one, two, three, four, five years or even more including the lifetime of the animal. The alpha-lipoic acid functions without any special protection in the diet such as encapsulation and need not be present in the diet in a unit dosage form such as those used in pharmaceuticals, for example. tablet, pill, capsule and the like. The lipoic acid is provided in the diet in a minimum of about 25, 50, 75, or 100 ppm of diet. The uppermost range is just below its toxic level, all the way down to about 400, 300, or 200 ppm of diet. Generally, one does not go beyond about 6 or 7 nig/kg body weight of animal per day, more generally not above about 5. The alpha-lipoic acid improves antioxidant defense capabilities as well as improves the animal's ability to resist oxidative damage. All this is done with the proper quantities of other antioxidants present such as vitamin E and vitamin C. This demonstrates that the action of alpha-lipoic acid is beyond that of vitamin C and/or vitamin E. EXAMPLE 3 Materials and Methods: [001051 Thirty (30) dogs were used to determine the effect of lipoic acid when compared to an AAFCO control food or a test food containing fish oil. [001061 A differently gene exprssion profile was studied between an AAFCO control food, atood containing fish oil, and a food containing lipoic acid. At a minimum of 1 .3 fold change, a list of 1212 genes was generated compared to the AAFCO control and 1896 genes PAXgene RNA isolatio kit. All measurements were done with the canine 2 Affymetrx WO 2010/078324 PCT/US2009/069686 was preformed using Partck. \n ANOVA -test was performed for genes that are differentially expressed between the control and test foods were selected based on p-value cutoff 01. fold change> >+/- 1.3. 1001081 Gene Expression: Expression of 121 genes was found to be altered in dogs fed a test food containing 150 ppm lipoic acid when compared to dogs fed an AAFCO control food. In addition, expression of 1896 genes was found to be altered in dogs fed the test food containing lipoic acid compared to a test food containing fish oil. Table 9 shows the genes grouped by function and the direction of expression relative to those fed either the control food or a food containing fish oil. 1001091 Metabolomics: Plasma metabolites were analyzed and were compared as fold change relative to the control fed dogs. [001101 Biomarker measurements: Serum cartilage markers were measured using ELISA based kits to determine concentrations of cartilage markers. Day 0 was used as a covariate in the analysis to adjust for baseline values. [001111 Results: The addition of lipoic acid to a food resulted in a greater decrease in type 11 collagen C-propeptide and carboxy-terminal crosslinked telopeptide fragment of type II collagen than a similar food without lipoic acid. These two markers are known to increase in dogs with osteoarthritis. Additionally, dogs fed a food containing lipoic acid lost fat suggesting an increase in utilization of fat for energy (fat oxidation) and a decreased production of glucose for healthier weight maintenance. In other words, dogs fed lipoic acid utilized available glucose more efficiently and shifted their metabolism towards mobilization of fat for energy use. Additionally, the metabolite hydroxyproline was reduced in plasma suggesting reduced cartilage destruction as this metabolite almost exclusively originates from cartilage. Furthermore, changes in gene expression as determined from serum white blood cells support the evidence to suggest increased cartilage protection from increased synthesis of cartilage components aind decreased expression of enzymes that degrade cartilage. Finally gene expression changes suggest improved fat utilization by increasing PDK4, which inhibits the formnation of pyruvatc from glucose and shifts metabolism to shuttling acetyl-C oA for energy, and upregulation of gluosetraspoter. Te dgs bd i piAcdasapeedeniavlairco aedt does ed te cotrolfood WO 2010/078324 PCT/US2009/069686 [001 12} The following tables show the difference in fat and weight as well as cartilage markers relative to treatment with lipoic acid. [001131 Table 4 illustrates the change in body composition of dogs fed a control diet compared vith dogs fed a control plus fish oil and a control plus lipoic acid. As illustrated in Table 4, dogs fed a control plus lipoic acid exhibited greatest change in weight over a 90 day treatment period.

WO 2010/078324 PCT/US2009/069686 Table 4. Change in body composition over 9 0 days Treatment Probability P < control Fish oil Fish oil vs Fish Lipoic vs vs lipoic Ihpoic Control oil acid SE Treatment Control acid acid Total weight, 14 400 14,500 13,800 4140 0_17 079 0.08 0.14 Change in weight g 444 160.4 -637.5 414.56 0.14 078 e 0.07 0.11 Total fat g 3245.6 3175.3 2788.3 281.01 0.23 0.80 0.18 0.11 Change in fat, g I-612 -666 -587,2 313 79 0.18 I 0.99 0.11 0.11 1001141 Table 5 illustrates the change in pyruvate blood levels in of dogs fed a control diet compared with dogs fed a control plus fish oil and a control plus lipoic acid. As illustrated in Table 5. dogs fed a control plus lipoic acid exhibited greatest change in pyruvate blood levels over a 30 day treatment period. Table 5. Fold change in pyruvate measured in the blood in dogs at day 30 fed three foodsa________ ____ __ Probability, P < + lipoic + lipoic Lipoic acid vs vs vs Metabolite Control Lipoic acid vs Control Fish oil Control upgrade P ruvate 1.000 0.5379 0.6274 0.01 0.03 aDay 0 values used as a covariate in the analysis 1001151 Table 6 illustrates the percentage of dogs classified as genomically fat after being fed a control diet compared with dogs fed a control plus fish oil and a control plus lipoic acid for 30 days. As illustrated in Table 6, dogs fed a control plus lipoic acid genomically did not resemble physically fat dogs after a 30 day treatment period. Table 6 Percentage. of Animals Classifying Genomicall Fat Pro Measure % Contro F[ ish Oi Lipoic Lipoic Lipoic Acid Acid vs. Acid vs. Control FishiO Percentage 30) 0 0 0.08 0.33 of animals at d30 that fa using

-

WO 2010/078324 PCT/US2009/069686 genomic markers {001161 Table 7 illustrates the change in blood level of arthritic markers in dogs after being fed a control diet compared w\ith dogs fed a control plus fish oil and a control plus lipoic acid for 30 days and measured again at day 90. As illustrated in Table 7, dogs fed a control plus lipoic acid displayed reduction in arthritic markers (i.e.. CPII and CTXI1) after a 30 day treatment period and a greater reduction in arthritic markers after a 90 day period of being fed a control plus lipoic acid. Table 7. Arthritic markers measured in the blood in dogs fed three different foods Probability P < Fish oil Lipoic acid Lipoic vs Fish oil vs vs Metabolite Control Fish oil acid SE Treatment Control Lipoic acid Control Day 30 CPIlI, ng/mL 1076.9 997.61 986.28 29.254 0004 0.01 0.70 0.01 Change CPII 17.00 -3050 -95.10 33.863 0.01 0.17 0.07 0.01 Change CTXII - 2

.

3 3 -0.03 -5.60 2.622 0.12 0.39 0.04 0.22 Day 90 CPIlI, ng/mL 941.1 897.8 848.0 33.56 0.02 018 0.15 0.01 Change CPII -118.70 -131.00 -23270 36.546 0.01 0,74 0.01 0.01 Change CTXII -3.24 -1.23 -0.59 6.119 j 0.90 0 7 092 0.67 Individual markers analyzed with d 0 as covariate LChangein individual markers and ratios anyzed without covariates. [001171 Table 8 illustrates the directional change (up regulation or down regulation) in genes related to cartilage metabolism in dogs after being fed a control diet compared with dogs fed a control plus fish oil and a control plus lipoic acid for 90 days in canine bone cells. As illustrated in Table 8. dogs fed a control plus lipoic acid displayed down regulation in MMP-3 gene corresponding to a degradation of the collagen component of cartilage, up-regulation of TIMP2 corresponding to inhibition of MMP's, and up regulation of proly I 4-hy droxy lase, which co rresponds to the rate limiting step in collagen type , synthesis (ie. produces hydroxyproline lr incorporation into collagen epiope. Table 8. Genes related to cartilage metabolism altered by lipoic acid in canine bone cells-.

Gene Pobe D rector a. ch ge unetron WO 2010/078324 PCT/US2009/069686 TIM02 1582708 a up _ n i bis MMPs Rate limiting step in collagen type 11 synthesis, produces hydroxyproline for Pjolyl 4-hydroxyase 1600479_at up incorporation into collagen eptope [001 18] Table 9 illustrates the change in genes related to cartilage metabolism and energy metabolism in dogs after being fed a control diet compared with dogs fed a control plus fish oil and a control plus lipoic acid for 90 days. Table 9. Genes related to cartilage and energy metabolism altered by lipoic acid compared to the control or upgrade foods (upgrade contains fish oil) Gene name Probe Fold lipoic acid vs. change Related to cartilage metabolism Prolyl hydroxylase alpha I CfaAffx.22481.l.Sl at. con Prolyl hydroxylase alpha 2 Cfa.13303.2.S1 a_at 1.3 control Facilitated glucose transporter Cfa.7132.1.A1 at 1.4 control 9 TIMPI Cfa.3680.1.SI s at control Chondroitan sulfate synthase 1 CfaAffx.16537.1 S1 at I control heparan sulfate N deacetylase/N sulfotransferase2 Cfa.11897.1.A1 at 1.3 control 12-lipooxygenase CfaAffx.25908.1.Sl s at -1.3 control chondroitan sulfate proteoglycan 2 (verisca1) Cf AffA3597.1,ST s at control Lysyl hydroxylase Cfa. 16732.1A I at 3 fish oil Cfa28621S at 1.3 fish oil acetylgalactosaminyItransferase Chondroitan sulfate synthase 1 C faAffx.1 6537 SlI at L3 f i o Fibronectin 3 Cfa 370712 S Iat 4is i c~~~ ~ onaittsuft proteog) can6 WO 2010/078324 PCT/US2009/069686 Gene name Probe Fold lipoic acid vs. change ADANI S-16 C faf x. 16270.1. S I at -1.3 fish oil l 2 -lipooxygenase Cfa ffd.25908.I1.Sl s at -1.3 fish oil NMP2 C tAff.14851l. SI s at -1.3 fish oil i N P7 CtaAftx.2320l.l.S1 at -1.3 fish oil ransforming growth factor Cfa.13340.1.A1 at 1.3 sh oil beta receptor I Facilitated glucose transporter Cfa.7132.Al at 1.4 fish oil 9 Related to energy metabolism PDK4 Cfa.2282.1.S1 at 1.4 control Cfa.19125.2.S1 at, Hexokinase 3 CfaAffx.25391.1.Sl s at 1.3 control 5* AMP alpha I Cfa.9738.1.S _s at 1.3 control 5' AMP beta 1 CfaAffx.15678.1.Sl at 1.3 control 5' AMP gamma 2 Cfa.10276.2.S1 a at, 1.4 control Facilitated glucose transporter CfaAffx.4630.l.Sl s at control Facilitated glucose transporter Cfa.6832.1.A 1 at 3 control 6 Sucinyl CoA ligase alpha Cfa.16185.1.S1 at 3 control PPAR gamma CfaAffx.8402.L S s at control Fatty acid desaturase 1 CfaAffx.24518.l.SI at 1.9 control cAMP responsice element Cfa.855.1.S1 at 1.3 fish oil modulator PDK4 Cfa.2282.l.S1 at 1.6 fish oil Cfa.19125.2SI _at. He 7olunase3 C fa f\.h25391.1.S sat 1.3 fish oil 5~~~~~~ IPl ga9 1. (.a i26.S I a a I. i i F ~clk~t~dJu~sc 'msprto ( a~f\ 430 1SI t Afis o7 Faciliated lucos tranporter (ti~.832. .A I at 14f i j _ ~~accin~~~~ 12 X1I.s.ah 'Y6 ~15 a iho WO 2010/078324 PCT/US2009/069686 Gene name Probe Fold lipoie acid vs. change Sueinl Co igase beta a148. . at 3ish oil PPAR gamma ICfaAIK842.1Sl s at 13 fish oil 3RBP-i Cfa189.2.Sl s at -1.3 fish oil [00119] Table 10 illustrates the ingredients in an illustrative pet food composition of the invention. Table 10. Ingredients used to make composition -Ingredients II Wheat 2 Milo 3 Corn 4 Ground Chicken 5 Corn Gluten Meal 6 Poultry Meal 7 Soy bean oil 8 Flaxseed Rice Brewers 10 Sovbean meal. 49% 11 Pal enhancer 1 12 __ Beet pulp 13 Potassium Citrate 14 Fish oil 15 DL-methionine 16 L-lysine HCI 17 ISalt 18 Calcium carbonate 20 Choline chloride 21 Vitami remix L-threonine 23 Vitamin 24 - -tryptophan 25 ipoic aci d_ 26 Mineral prermhx 27 Preserve ative [01i2O} Table 11 illautates immune status makers in blood samples for do>gs after bemg fed a control diet compared w iho dogs fed a conmrol plub lipoi acid for 90 da) S. ~iustrated in Table 11, dogs fed a food including lipoic acid displayed increased i mmune status maurkers aner 90 days 2 8 ---------- WO 2010/078324 PCT/US2009/069686 Table 11. Immune statusmarkers measured In the blood m dogs at da 90. SProbabihity P - Utpgrade

-

tipoi Upgrade vs > tUpgrade control vs M_____etabolite Connol acid S Control Vs Ipuie Lipoic Vitamin LmL 24 15 30.47 34.51 3.318 0.07 0.23 0.01 Vitamin E: Cholesterol 0.29 0.51 0.55k 0.074 0.01 0.67 0.01 Vitamin ES: T igly eride - 0.14 0.17 0. 17 0.009 0.01 .62 0.01 *Day 0 values used as a covariate in the analysis - Control refers to standard AAFCO dog food. - Upgrade refers to a low fat, reduced calorie, high fiber pet food. [00121] Table 12 illustrates arthritic makers measured in blood samples for dogs after being fed a control diet compared with dogs fed a pet food including lipoic acid for 90 days. As illustrated in Table 12, dogs fed a control plus lipoic acid displayed decreased immune status markers after 90 days. Table 12. Arthritic markers measured in the blood in dogs at day 90 fed different foods" Probability, P < -_ -------- -I -~--

-

------- -- - -------- UpgradeI Upgrade+ vs Upgrade control vs Metabolite Control Ugrade lipoic SE Control vs +lipoic +-ipoic CPI, ng/rmL 941.1 897.8 848.0 33.56 0.18 0.15 0.01 COMP,0.088 0.04 0.28 0.30 CPIl:COMP ratio 535.3 460.4 483.3 41.78 0.08 0.59 0.22 Change CPHI -118 70 -131.00 -232.70 36.546 0.74 0.01 0.01 4- -------- __ ChangeCOMP -1.53 -1.31 -1.39 0.153 0.17 0.60 0.39 Eico sapentaenoi e

-

Acid m/dl 0.15 9.88 10.4 1.259 0.01 0.69 0.01 ndidual markers analyzed with d 0 as covariate_______ ___ <Chang in individual marker and ratios an alyzed without covaniates. - Contro' refers to standard AAFCO dog food. -_Upgrade refers to a low fatreduced calori 'high fiber e od--------__ [00122] Table 13 illustrates skin and coat makers measured in blood samples for dog ater being fed a conmol diet compared wih dogs fed a pet food including lipoic acid for 90 days. As illustrated in Table 13, dogs fed a control plus lipoic acid displayed increased skin and coat markers after 90 days. -729 WO 2010/078324 PCT/US2009/069686 Table 13. Skin and coat m re mIIt bo InI dg at Jl_ )._ 71pgrde I grade vs L ra7ide control vs letabolite Control upgrade lipoic Control lipoic 1poi Vitamin ES pg4mL 4.15 30.47 34.51 3.318 0.07 0.23 0.01 Vitamin E: Cholesterol 0.29 0.51 0.55 0.074 0.01 0.67 0.01 Vitamin E: Triglyceride 0.14 0.17 0.17 0.009 0.01 0.62 0.01 Linoleic Acid, mg/dL 55.22 61.51 66.02 5.062 0.23 0.38 0.04 Eicosapentaenoic Acid, mg/dL 0.15 9.88 10.4 _ 1.259 0.01 0.69 0.01 Doeosahexaenoic Acid. mgjdl 1.38 11.07 11.56 1.419 0.01 0.74 0.01 Arachodonic acid, mg/dt 54.57 34.65 __ 37.67 - 5.074 0.01 0.56 0.01 *Day 0 values used as a covariate in the analysis. - Control refers to standard AAFCO dog food. - Upgrade refers to a low fat, reduced calorie, high fiber [001231 Table 14 illustrates kidney makers measured in blood samples for dogs after being fed a control diet compared with dogs fed a pet food including lipoic acid for 90 days. As illustrated in Table 14, dogs fed a control plus lipoic acid displayed decreased kidney markers after 90 days. Table 14. Kidney markers measured in the blood in dogs at day 90 fed three Probabilit P < C____ 2.8_ pg r 2 upgrade ' Blet - ipe P±lioc (_x etion 6~ 4.2 i2.~6 22 84 2 A 0.2 A4 (98 - .01 Blood I rea Nitro en WO 2010/078324 PCT/US2009/069686 Day 0 values used as a cov ariate in thc analysis. - Control refers to standard A \EC) dog food. - ypgrade refers to a low fat. reduced calorie. high fiber pet food [001241 Table 15 illustrates Dual Energy X-Ray Absorptiomctry (DEXA) measurement for dogs after being fed a control diet compared with dogs fed a pet food including lipoic acid for 90 days. The measurement of body fat using DEXA is more accurate than body weight for assessing health. A dog can have a lot of muscle, but be considered "over-weight" by many height/w eight charts. The opposite can also be true - a dog can have a lot of fat and little muscle and be "over-fat" but not overweight. Table 15. Canine Nutrigenomics DlA (Dual Energy X-Ray sorptiometry) at day 90 v ith initial as covariate Treatment Probability. P < Upgrade Upgrade Upgrade vs vs control vs Control Upgrade tlipoic SE Control +ipoic +lipoic Total weight. k 14.4 14.5 13.8 0.41 0.79 0.08 0.14 Food intake, g 303.1 1___306.4 269.9 25.963 0.90 0.17 0.21 Body condition score 33 3.2 3.2 0.198 10.62 0.99 0.62 BMC 477.61 464.5 6.981 0.62 0.07 0.18 BMD g 0.89 0.90 0.88 0.012 0.43 0.20 0.61 ea 10699 10820 10558 220.73 0.59 0.25 0.53 S% fat 21.54 21.59 20.69 1.643 0.98 0.59 0.61 Total fat g 3245.6 3 175.3 2788.3 281.01 0.80 0.18 011 Lean:fat ratio 4.15 4.20 4.25 0.425 0.90 0.92 0.82 3.3 3.3 3.3 0.10 0,78 0.67 0.48 % lean 74.8 75.4 76.4 1.50 0.67 0.48 0.26 *Day 0 used as a co5ariate -Control refers to standard AAFCO dog fod -.pgrade refers o a iow fat educed calorie, igfber pe ood [00125) Table 16 illustratoes immune status and antioxidant makers measured nf WO 2010/078324 PCT/US2009/069686 ... Probabilit'. P < \etabolite 1 2 #3 -4 5 12 \s #4LS~5 (Glutathionine peroxidase, pg 10 5.44 5.96 74 5.65 5.35 0401 NS NS NS NS Vitamin

-

. SL8.65 37.03 29.5 411 4 23.35 2.377 N S 0.05 0.05 0.05 Vitamim 1: Cholesterol 0.15 0.20 0 15 020 013 0.009 \ S 0.05 0.05 0.05 VitaminE . I rnglyceride 0.27 L 0.29 0.31 0.37 0.19 0.062 NS NS NS NS *Day 0 used as a covariate - Control refers to standard AAFCO dog food. - Upgrade refers to a low fat, reduced calorie, high fiber pet food [00126] Table 17 illustrates arthritic makers measured in blood samples for dogs after being fed five different foods for 180 days. Table 17. Arthritic markers measured in the blood in dogs at day 180 fed five different foods* Probability,. P Vs vs Metabolite #1 42 #3 ;4 45 SE vs 1 x s "2 #4 15 Osteocalcin. ngmL 6.81 8.64 9.53c 8.29 6.71 0.883 0.05 NS NS 0.05 Cartilage Oligomeric Matrix Protein, L.L 3.17 3.30 3.23 3.19 3.38 0.204 NS NS N NS Amino'Terminal Crosslink Telopeptide, aM BCE 21.42 25.53 24.89 24.02 23.63 2.707 NS NS NS N Cicosapentaenoie 1 Acid. mgdL 1.88b (.41) 8.07c 1.79b 0.47 0.388 0.05 0.05 0.05 0.05 *Dav0 used as a cox'ariate [00127] Table 18 illustrates sk n and coat makers maured in blood samples for dogs after being fed five different dog foods for 1 80 day s. -~~~ --------. --- -L ------- __ y , 1 l\ i s g ~i-T L~C >f 41~4 ' .3. .o5 0.u n~~~~~~~~~---- -- --- .0~ .0 1 ~ 00 .5 00 WO 2010/078324 PCT/US2009/069686 ( ho en I iexerde 07 0.9 03 13 .19 0.!6 SN __ N Linoleic \id. _mgdl i 51.67 384622 0198 2.9 0.05 0.05 0.05 0.05 I ieosapentae noic \cid. medt .88 0.49 8.0 .47 (188 0.05 0.05 0.05 0.05 Do1osahe90e nole \cid. mg dL 1036_268 13.4 .186 2.01 0.646 0.05 _ 0.05 1 0.05 0.05 [001281 Table 19 illustrates kidney makers measured in blood samples for dogs after being fed five different pet foods for 180 days. Table 19. Kidnev markers measured in the blood in dogs at day 180 fed live different foods Probabilit. P< Metabolite A1 42 ' 4F 45 SE I vs2 Vs#4 vs#5 L rine specific gravity 1.032 1.028 1.032 1.032 1.032 0 0047 S NS NS NS LRD (healthy (0) vs unhealthy (1,23)count) 0 1 0 2 0 N S NS NS NS Blood U1rea Nitrogen Creatinine 18.78 19. 50 19.86 2112 19,38 1.070 NS NS NS NS Blood U rea Nitrogen. mgidL 14.3 14.64 14.27 16.22 13.54 0.831 NS NS 0.05 NS Creatinine, I |mg dL _ 0.75 0.75 0 72 0.78 0.70 0.034 NS NS S *Da 0 values used as a coariate in the analyst [001291 Table 20 illustrates body composition at day 180 to determine treatment effect with initial covariate for dogs fed five different pet foods for 180 days. Table 20. Canine body composition at day 1 80 Adult treatment effect ' ith initial covariate Treatment .Probabilit #1 #2 #4 #5 E vs# vs VsX, # s#5 BMC g 419 78 395.51 400.1 442.07 393.07 24.95 L0.05 NS NS 0.05 BMD. g 0.601 0.584 0.(587 0.623 0.577 0.0185 NS NS NSE0.0 lean 7929 7~631 7 7 5 8 7 9 8 2 7 3 8 0 a 4 7 9

.

6 _NS NS NS NS__ Total fat 2726 2843 3012 -,3361 2945 365.6* NS NS N S NS Total waeight.

WO 2010/078324 PCT/US2009/069686 i ean fat ratio 3.28 -3.0 2.86 2.57 2,95 0.405 NSN NS S % iMC 3.85 3,7 67 74 0.101 V NS NS lean 72.9 723 71.1 68.0 70.6 2.60 N _ [001301 Table 21 illustrates blood cytokine levels at day 180 to determine treatment effect with initial covariate for dogs fed five different pet foods for 180 day s. Table 21. Canine blood eytokine levels at d 180 with d 0 as covariate Probability, P < measure I1 #2 1 3 !4 #5 SE Vs l vs 2 Vs44 Vs#5 I-22 (pg/nil) 635.2 251.60 263.9 371.00 257.10 394.21 0.20 0.97 0.98 0.77 IL-6 08 ( ml) 103.7 66.8 45.9 41.7 66.50 48.606 0.11 0.55 0.55 0.93 IL-7 (pg/ml) 369.0 235.9 215.7 661.6 210.4 200.49 0.30 0.89 0.97 0.02 IL-8 g/ml 989.8 885.0 1024.3 1261.1 833.3 227.10 0.82 0.37 0.21 0.24 11-15 (pg/ ml) 477.8 390.8 280.5 476.0 374.7 247.07 0.28 0.53 0.59 0.39 IL-18 (pg/ml) 458.7 200.6 172.4 297.5 262.5 238.53 0.10 0.87 0.60 0.57 KC (pg'ml) 803.6 643.6 653.9 592.6 589.0 105.65 0.05 0.89 0.38 0.54 MCP-1 (pg/ml) 349.2 216.8 215.4 1 223.7 256.2 108.13 0.09 0.99 0.60 0 93 IP-10 (pg/ml) __ 6.05 7.93 3.98 7.76 2.89 3.572 0.41 0.12 0.68 0.25

IFN

gamma (pg/ml) 31.88 29.61 15.07 9.03 19.79 25.207 0.36 0.42 0.79 0.80 GM-CSF I _________j27. 23.7 ______ 0788 0.65 (,jp/Il) 620.9 217.22 351.8 284.2 301.51 0.08 0.98 0.78 Total Pro inflammatory estokines 5351.1 2394.10 2832.2 4535.5 3284.1 1482.30 0.02 _ 0.

7 0 0.

6 8 0

.

2 2 dogs after being fed a control diet compared with dogs fed a pet food including lipoic acid 4Table 22 dd 34 WO 2010/078324 PCT/US2009/069686 Pr obabilitx. P upgrade Upgrade Upgrade x ..pgrade s s v as fish \letabolite Control Conol l Fish oil Control oil P\ruate 1.0 0._54 0.63 1.01 0.03 l P droy\ proline 1.0 0.54 0.90 0.01 0.2 3-Indoxylsulfuric acid 049 . 085 0.10 0.78 1.5anhydrosorbitol 1.0 0.75 1.10 0.01 0.33 Nervonic acid 1.0 1.40 1.05 0.01 0.24 Alpha-tocopherol 1.0 1.30 0.96 0.01 0.88 Coenzyme Q10 1.0 1.84 1.29 0.01 0.13 Allantoin 1.0 0.97 1.25 0.78 0.02 Creatine 1.0 0.78 1 .50 0.06 0.20 Taurine 1.0 .41 0.98 0.01 0.98 'Day 0 values used as a covariate in the analysis. - Control refers to standard AAFCO dog food. - Upgrade refers to a low fat, reduced calorie, high fiber pet food [001321 The invention is not to be limited in scope by the specific embodiments disclosed in the examples, which are intended as illustrations of a few aspects of the invention, and any embodiments, which are functionally equivalent, are within the scope of this invention. Indeed, various modifications of the invention in addition to those shown and described herein will become apparent to those skilled in the art and are intended to fall within the appended claims. [001331 For any references that have been cited, the entire disclosures of which are incorporated herein by reference.

Claims (66)

1. A pet food composition comprising an effective amount of lipoic acid to prevent or treat a degenerative joint condition in a companion animal in need thereof. wherein said effective amount of lipoic acid to prevent or treat a degenerative joint condition is at least 25 ppm.

2. The composition of claim 1, wherein the amount is at least about 50 ppm.

3. The composition of claim 1, wherein the amount is at least about 100 ppm.

4. The composition of claim 1. wherein the amount is about 100 ppm to about 600 ppm.

5. The composition of claim 1, wherein the amount is about 100 ppm to about 200 ppm.

6. The composition of claim 1, wherein the companion animal is a dog.

7. The composition of claim 1, wherein the companion animal is a cat.

8. The composition of claim 1, wherein the degenerative joint condition comprises osteoarthritis.

9. The composition of claim 1. wherein the degenerative joint condition comprises cartilage damage.

10. A pet food composition comprising an effective amount of lipoic acid to modulate enzymatic degradation of articular cartilage in a companion animal in need thereof, wherein said effective amount of lipoic acid to modulate enzymatic degradation of articular cartilage is at least 25 ppm.

11. The composition of claim 10, wherein the amount is at least about 50 ppm.

12. The imposition of claim 10, wherein the amot is at lt aot 100 ppm. WO 2010/078324 PCT/US2009/069686

14. The composition of claim 10, wherein the amount is about I 0 ppm to about 200 ppm.

15. The composition of claim 10, wherein the companion animal is a dog.

16. The composition of claim 10, wherein the companion animal is a cat.

17. A pet food composition comprising an effective amount of lipoic acid to maintain or increase bone mineral density in a companion animal, wherein said effective amount of lipoic acid to maintain or increase bone mineral density is at least 25 ppm.

18. The composition of claim 17. wherein the amount is at least about 50 ppm.

19. The composition of claim 17, wherein the amount is at least about 100 ppm.

20. The composition of claim 17, wherein the amount is about 100 ppm to about 600 ppm.

21. The composition of claim 17, wherein the amount is about 100 ppm to about 200 ppm.

22. The composition of claim 17, wherein the companion animal is a dog.

23. The composition of claim 17, wherein the companion animal is a cat.

24. A pet food composition comprising an effective amount of lipoic acid to prevent or treat kidney-related disorders in a companion animal. wherein said effective amount of lipoic acid to prevent or treat kidney-related disorders is at least 25 ppm.

25. The composition of claim 24, wherein the amount is at least about 50 ppm.

26. The cmposition of claim 24. wherein the amount is at least about 100 ppm.

27. The composition of claim 24, wherein the amount is about 100 ppm to about 600 ppm

28. The composition of claim 24, wherein the amount is about 100 ppm to about 200 ppm.

29. Tecnpstu eam2,weentecmainaia sadn 7) WO 2010/078324 PCT/US2009/069686

30. The composition of claim 24, wherein the companion animal is a cat.

31. A pet food composition comprising an effective amount of lipoic acid To enhance palatability to a companion animal, w herein said effective amount of lipoic acid to enha nce palatability is at least 25 ppm.

32. The composition of claim 31, wherein the amount is at least about 50 ppm.

33. The composition of claim 31, wherein the amount is at least about 100 ppm.

34. The composition of claim 31, wherein the amount is about 100 ppm to about 600 ppm.

35. The composition of claim 31, wherein the amount is about 100 ppm to about 200 ppm.

36. The composition of claim 31, wherein the companion animal is a dog.

37. The composition of claim 31. wherein the companion animal is a cat.

38. A pet food composition comprising an effective amount of lipoic acid to maintain or promote a healthy body composition in a companion animal. wherein said effective amount of lipoic acid to maintain or promote a healthy body composition in a companion animal is at least about 25 ppm.

39. The composition of claim 38, wherein the amount is at least about 50 ppm.

40. The composition of claim 38, wherein the amount is at least about 100 ppm.

41. The composition of claim 38, wherein the amount is about 100 ppm to about 600 ppm. ppm. 4~ 3. WO 2010/078324 PCT/US2009/069686

45. A pet food composition comprising an effective amount of lipoic acid to induce weight loss in a companion animal, wherein said effective amount of lipoic acid to induce weight loss in a companion animal is at least about 25 ppm.

46. The composition of claim 45, wherin the amount is at least about 50 ppm.

47. The composition of claim 45, wherein the amount is at least about 100 ppm.

48. The composition of claim 45, wherein the amount is about 100 ppm to about 600 ppm.

49. The composition of claim 45, wherein the amount is about 100 ppm to about 200 ppm.

50. The composition of claim 45, wherein the companion animal is a dog.

51. The composition of claim 45, wherein the companion animal is a cat.

52. A pet food composition comprising an effective amount of lipoic acid to increase the percentage of lean muscle mass in a companion animal, wherein said effective amount of lipoic acid to increase the percentage of lean muscle mass in a companion animal is at least about 25 ppm.

53. The composition of claim 52. wherein the amount is at least about 50 ppm.

54. The composition of claim 52, wherein the amount is at least about 100 ppm.

55. The composition of claim 52, wherein the amount is about 100 ppm to about 600 ppm.

56. The composition of claim 52, wherein the amount is about 100 ppm to about 200

57. The composition of claim 52, wherein the companion animal is a dog.

58. The composition of claim 52, wherein the companion animal is a cat.

59. A pet food compositon comprising an effective amount of lipolc acd wherei s a effective amount of lipoic acid is at least 25 ppm. 5&- WO 2010/078324 PCT/US2009/069686

60. The composition of claim 59, wherein the amount is at least about 50 ppm.

61. The composition of claim 59, wherein the amount is at least about 100 ppm.

62. The composition of claim 59, wherein the amount is about 100 ppm to about 600 ppm.

63. The composition of claim 59, wherein the amount is about 100 ppm to about 200 ppm.

64. The composition of claim 59, wherein the companion animal is a dog.

65. The composition of claim 59, wherein the companion animal is a cat.

66. The composition of claim 59. wherein the composition is useful for prevention or treatment of detrimental conditions in a companion animal in need thereof.

67. The composition of claim 66, wherein the detrimental conditions comprise degenerative joint condition, modulation of enzymatic degradation of articu lar cartilage, maintenance or decrease bone mineral density, kidney-related disorders, reduced palatability, unhealthy body composition, obesity, decreased percentage of lean muscle mass in a companion animal in need thereof.

68. The composition of claim 67, wherein the degenerative joint condition comprises osteoarthritis.

69. The composition of claim 67, wherein the degenerative joint condition comprises cartilage damage.

70. The composition of claim 67. where the obesity is treated or prevented by inducing eight loss in the companion animal.